Table 2.
Association of the PTGS2 rs5275 polymorphism with invasive ovarian carcinoma risk by study and ethnicity and in all women combined
| Study and ethnicity |
No. cases (%) by genotype | No. controls (%) by genotype | Heterozygotes and rare allele homozygotes* | Log-additive model | Recessive model | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TT | TC | CC | TT | TC | CC | TC OR (95% CI)† |
CC OR (95% CI) † |
P 2 d.f. |
Per C allele OR (95% CI) † |
P 1 d.f. |
CC vs TT+TC OR (95% CI) † |
P 1 d.f. |
|
| HAW/All | 169 (56) | 120 (40) | 13 (4) | 338 (57) | 207 (35) | 47 (8) | 1.08 (0.79-1.46) | 0.52 (0.26-1.02) | 0.12 | 0.89 (0.70-1.13) | 0.34 | 0.51 (0.26-0.98) | 0.04 |
| HAW/ with NSAID data available |
117 (54) | 88 (41) | 12(5) | 233 (56) | 150 (36) | 36 (8) | 1.12 (0.78-1.61) | 0.65 (0.32-1.35) | 0.35 | 0.95 (0.72-1.24) | 0.68 | 0.62 (0.31-1.16) | 0.19 |
| HAW/White | 34 (49) | 33 (47) | 3 (4) | 75 (49) | 60 (39) | 19 (12) | 1.16 (0.62-2.19) | 0.38 (0.10-1.42) | 0.26 | 0.83 (0.52-1.32) | 0.42 | 0.35 (0.10-1.29) | 0.11 |
| HAW/Asian | 88 (61) | 49 (34) | 7 (5) | 173 (61) | 92 (33) | 17 (6) | 1.01 (0.64-1.60) | 0.85 (0.32-2.27) | 0.95 | 0.97 (0.68-1.39) | 0.86 | 0.85 (0.32-2.23) | 0.74 |
| HAW/Other | 47 (53) | 38 (43) | 3 (4) | 90 (58) | 55 (35) | 11 (7) | 1.05 (0.57-1.92) | 0.31 (0.07-1.35) | 0.27 | 0.80 (0.49-1.31) | 0.37 | 0.30 (0.07-1.29) | 0.11 |
| NECC/White | 333 (46) | 304 (42) | 86 (12) | 490 (45) | 469 (43) | 136 (12) | 0.94 (0.77-1.16) | 0.93 (0.68-1.25) | 0.82 | 0.96 (0.83-1.11) | 0.82 | 0.96 (0.71-1.28) | 0.77 |
| All White | 367 (46) | 337 (43) | 89 (11) | 565 (45) | 529 (42) | 155 (13) | 0.98 (0.80-1.18) | 0.89 (0.66-1.20) | 0.75 | 0.95 (0.83-1.09) | 0.48 | 0.90 (0.68-1.20) | 0.47 |
| All combined | 502 (49) | 424 (41) | 99 (9) | 828 (49) | 676 (40) | 183 (11) | 1.01 (0.85-1.19) | 0.86 (0.65-1.14) | 0.44 | 0.95 (0.85-1.08) | 0.44 | 0.86 (0.66-1.12) | 0.26 |
|
| |||||||||||||
| ‡P for heterogeneity among ethnic groups | 0.80 | 0.68 | 0.99 | 0.60 | |||||||||
|
| |||||||||||||
| ‡P for heterogeneity between studies | 0.36 | 0.15 | 0.73 | 0.10 | |||||||||
*
TT genotype was used as the reference group
†
Odds ratios (OR) and 95% confidence intervals (OC) adjusted for age, ethnicity, education, family history of breast and/or ovarian cancer, menopausal status, use of contraceptive and menopausal hormones and, in the combined analysis, study.
‡
P for heterogeneity of the association of the rs5275 with risk by ethnicity and study strata was estimated using a Wald test of the genotype-stratum interaction term
Note: statistically significant estimates (p<0.05) are presented in bold font